Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T3011 oncolytic herpes simplex virus injection plus PD-1/PD-L1 inhibitor in advanced solid tumors (Ib/IIa, single-arm, China)
CTR20233906Phase 2Active
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Jan 2024
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MVR-T3011 in Nonhematologic neoplasms and head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoints: Safety and Objective response rate (ORR). Started Jan 2024; status: active.
02
Drugs
MVR-T3011
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20233906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233906.